10-Q: Electromedical Technologies Reports Q3 2024 Results Amidst Transition to New Product

Electromedical Technologies experienced a significant decrease in sales during the third quarter of 2024 as it transitions to its new Wellness Pro Infinity product.

Summary

• Electromedical Technologies reported a net loss of $724,643 for the three months ended September 30, 2024, compared to a net loss of $376,720 for the same period in 2023.
• Net sales decreased by 87% to $42,526 for the quarter, down from $323,613 in the prior year, primarily due to reduced unit sales as the company winds down sales of its current product.
• The company's operating expenses decreased by 16% to $411,683, driven by lower commissions, payroll, and other operating expenses, partially offset by increased consulting and professional fees.
• For the nine months ended September 30, 2024, the net loss was $1,329,681, compared to $2,292,589 in 2023.
• Net sales for the nine-month period decreased by 43% to $570,415, down from $997,213 in the prior year, due to lower unit sales and reduced average selling prices.
• Operating expenses for the nine-month period decreased by 54% to $1,209,046, primarily due to reduced payroll, consulting, research and development, and other operating costs.
• The company has collected $764,125 in customer deposits for the new Wellness Pro Infinity product as of September 30, 2024.
• The company has a working capital deficit of $3,787,034 and cash on hand of $34,809 as of September 30, 2024.
• The company is in default on a matured convertible promissory note with principal and interest due of $93,000 and $51,099 respectively, and is in negotiations with the lender to reform the note.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant revenue decline, net losses, and a substantial working capital deficit. The company's reliance on future funding and the default on a convertible note further contribute to a negative outlook.

Positives

• Operating expenses decreased significantly for both the three and nine-month periods, indicating cost-cutting measures.
• The company has secured $764,125 in customer deposits for the new Wellness Pro Infinity product, showing customer interest.
• The net loss for the nine months ended September 30, 2024, decreased compared to the same period in 2023, indicating some improvement in financial performance.
• The company has entered into settlement agreements with some lenders, modifying debt terms and reversing default penalties.

Negatives

• Net sales decreased significantly for both the three and nine-month periods, indicating a decline in revenue generation.
• The company experienced a net loss for both the three and nine-month periods, indicating ongoing financial challenges.
• The company has a significant working capital deficit, raising concerns about its short-term financial stability.
• The company is in default on a matured convertible promissory note, indicating potential financial distress.
• The company's internal controls over financial reporting were deemed ineffective as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on securing additional funding.
• The company faces significant uncertainty regarding its ability to achieve positive cash flows from operations.
• The company's reliance on a few key customers and suppliers poses a concentration risk.
• The company's convertible promissory notes contain variable conversion provisions upon default, which could lead to further dilution.
• The company's internal controls over financial reporting are not effective, which could lead to errors in financial reporting.

Future Outlook

The company expects to obtain funding through additional debt and equity placement offerings until it consistently achieves positive cash flows from operations. The company is focused on the launch of its new Wellness Pro Infinity product.

Management Comments

• Management is of the opinion that no asset is likely to be realized for an amount less than the amount at which it is recorded in the financial statements as at September 30, 2024.
• Management is seeking to raise additional working capital through various financing sources, including the sale of the company's equity and/or debt securities.
• Management believes that the company's continuing viability is dependent upon growing its revenue base and/or accessing additional sources of capital, and/or selling assets.

Industry Context

The company operates in the bioelectronics industry, which is a developing field of electronic medicine. The company aims to offer alternatives to addictive pain-relieving drugs, such as opioids, which is a significant issue in the healthcare industry.

Comparison to Industry Standards

• It is difficult to make a direct comparison to industry standards without specific data on comparable companies in the bioelectronics sector.
• However, the significant decrease in sales and the substantial net losses indicate that the company is underperforming compared to industry benchmarks for revenue growth and profitability.
• The company's reliance on debt financing and the default on a convertible note suggest a higher level of financial risk compared to more established companies in the medical device industry.
• The lack of an audit committee and the identified material weaknesses in internal controls are also concerning when compared to best practices in corporate governance.

Corporate Governance

Legal Proceedings

• There are unasserted claims between the company and one of its lenders that could possibly exceed $5,000.
• The lender has notified the company that, due to defaults, the default amounts under the note, including principal, accrued interest, default interest, and legal fees, multiplied by 150% is being sought.
• The company is in negotiations with the lender to reform the note in default.

Related Party Transactions

• In January 2023, the company issued one share of Series B Preferred stock to the company's CEO, with a compensation expense of $400,000.
• The CEO's salary was reduced from $365,000 to $265,000 per year, with unpaid sums being accrued and subject to an option to convert into shares.
• In February 2023, the company entered into a consulting agreement with an advisor and director in exchange for 35 million shares of common stock.

Stakeholder Impact

• Shareholders face the risk of further dilution due to potential equity offerings and convertible note conversions.
• Employees may be affected by cost-cutting measures and potential restructuring.
• Customers may be impacted by the transition to the new product and potential supply chain disruptions.
• Creditors face the risk of non-payment due to the company's financial difficulties and defaults.

Next Steps

• The company plans to continue its efforts to grow its revenue base.
• The company will continue to seek additional sources of capital.
• The company will focus on the launch of its new Wellness Pro Infinity product.
• The company is in negotiations with a lender to reform a note in default.

Key Dates

Keywords

Electromedical Technologies, bioelectronics, medical devices, pain management, financial results, net loss, sales decrease, operating expenses, convertible notes, working capital, customer deposits, internal controls, default, Wellness Pro Infinity